In our setting, treatment of mice bearing an immunogenic tumor (EG.7-OVA) with anti-PDL1 and anti-PDL2 Abs increased the frequency of circulating IFNγ-secreting CD8+ T cells but had scarce effect on tumor-specific immunity and no therapeutic advantage over placebo. Here, PDCD1LG2 is linked to neoplasm.